近期跟踪公司
2seventybio，Abbvie，Alnylam，Amgen，ALX oncology，Argenx，Astrazeneca，Avidity，Bluebird，BMS，Biogen，Eisai，Eli Lilly，Genentech，Gilead，HCA，J&J，Legend，Medtronic，Merck, Moderna，Novartis，Pfizer，Pliant，Regeneron，Roche，Sanofi，Sarepta，Vertex
Biotech中概股纪要：
Transcript : I-Mab, H1 2023 Earnings Call, Aug 17, 2023
August 17, 2023 at 08:00 am EDT
Tyler Ehler (Executives)
Good morning, everyone, and thank you for joining us this morning and for standing by. I'd like to take this opportunity to welcome you all to the I-Mab Biopharma midyear 2023 financial results and business update conference call. My name is Tyler Ehler, and I'm I-Mab's Senior Director for Investor Relations. [Operator Instructions]
At end of this call, we will conduct a Q&A session and instructions will follow at that time. Earlier today, we issued a press release providing a review of our financial results for the midyear ended June 30, 2023, as well as an overview of our recent corporate highlights and upcoming milestones. The press release can be accessed on the Investor Relations tab on our website at ir.i-mabbiopharma.com.
Joining me today on the call from I-Mab's senior management team are Raj Kannan, CEO; Dr. John Hayslip, Chief Medical Officer; Dr. Andrew Zhu, President and Head of R&D; and Richard Yeh, Interim CFO and COO.
Raj will provide a high-level overview of our recent achievements and upcoming milestones, and John will provide an update on our R&D progress. Richard will then provide a summary of our financial results for the 6 months ended June 30, 2023, before we turn the call over to Raj for a few final comments. And then back to the operator to take your questions.
Please note that today's discussion will contain forward-looking statements relating to the company's future performance and the forward-looking statements are made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to certain risks and uncertainties, assumptions and other factors. Some of these risks are beyond the company's control and could cause actual results to differ materially from those mentioned in today's press release and on this earnings call.
A general discussion of the risk factors that could affect I-Mab's business and financial results is included in certain filings of the company with the Securities and Exchange Commission, including, but not limited to, the Risk Factors section in I-Mab's most recent annual report on Form 20-F as well as discussions of potential risks, uncertainties and other important factors in I-Mab's subsequent filings with the SEC.
Moreover, we operate in an evolving environment. New risk factors emerge from time to time, and it's not possible for us to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor or a combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in today's press release and on this earnings call relate only to the events or information as of the date on which the statements are made. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
We'll also discuss specific non-GAAP financial measures during today's call. The presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. Please see the financial results press release issued earlier today for a definition of non-GAAP financial measures and a reconciliation of GAAP to non-GAAP financial results.
And with that, I'll now turn the call over to our CEO, Raj Kannan. Raj, please go ahead.
Presenter SpeechRaj Kannan (Executives)
Thank you, Tyler, and good morning, everyone, and thank you for joining us. It has been an energizing few weeks for me since I came on board as CEO in June. I came to this new role with much confidence in I-Mab's innovative programs and an understanding that we have a great deal of work ahead of us.
Today, I'm pleased to speak with you and set out a clear direction for I-Mab that could potentially unlock the significant inherent value that I see in this company for our shareholders. During our call, I will provide you with a high-level update on our performance in the first half of 2023 and importantly, frame our strategic direction and plan. I will ask John Hayslip, our Chief Medical Officer, to provide you with an update on the 2 prioritized clinical assets in Oncology that we plan to rapidly advance in the U.S. and globally and finally, review the recently released positive Phase III results from our lead program in China. Richard Yeh, our Interim Chief Financial Officer, will review the financial results for the first 6 months of 2023 and then hand it back to me for closing remarks.
精彩评论